Shares of Kairos Pharma Ltd. (KAPA), which gained nearly 6.29 % yesterday, are up another 20% in premarket hours today, trading at $1.92.
This clinical-stage biopharmaceutical company focused on developing cancer therapies will be presenting a talk on its investigational compound KROS 101 at the 13th AACR-JCA Joint Conference tomorrow.
KROS 101 is a small molecule agonist designed to target the GITR ligand and improve immune responses against tumors. It is under preclinical development.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.